Breakthrough in diabetes care: Roche’s Susvimo could revolutionize eye treatment
Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda and Pavilion studies, showcasing the sustained efficacy ... Read More
Roche bags CE Mark for Accu-Chek SmartGuide CGM solution
Roche has announced a significant advancement in diabetes management with the CE Mark approval of its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This approval ... Read More
Genentech announces reintroduction of Susvimo for Wet AMD treatment in US
Genentech, a key member of the Roche Group, has officially announced the reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, a cutting-edge treatment for wet, or ... Read More
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More
FDA approves Roche’s Vabysmo prefilled syringe for eye diseases, expanding treatment options for millions
Roche (SIX: RO, ROG; OTCQX: RHHBY), a global leader in pharmaceuticals and diagnostics, announced a significant advancement in eye care with the U.S. Food and ... Read More
Roche’s Columvi extends survival in Phase III DLBCL study
Roche has revealed promising outcomes from its Phase III STARGLO study, showcasing significant advancements in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with ... Read More
LIXTE Biotechnology advances colon cancer treatment with Roche and Netherlands Cancer Institute
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a trailblazer in clinical stage pharmaceutical development, has embarked on a groundbreaking clinical trial in partnership with ... Read More
Roche and Hitachi High-Tech strengthen partnership with a renewed 10-year agreement
Roche and Hitachi High-Tech have announced a significant extension of their partnership, solidifying at least another decade of collaboration in the field of in-vitro diagnostics. ... Read More
Roche’s CT-388 shows promising results in Phase I trial for obesity and Type 2 diabetes treatment
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a ... Read More
Roche gains FDA approval for HPV self-collection kit to enhance cervical cancer screening
Roche has achieved a significant milestone with the FDA approval of its innovative human papillomavirus (HPV) self-collection solution, positioning it as one of the first ... Read More